10-Q quarterly report · filed Oct 30, 2026

ResMed (RMD) Q3 2026 10-Q Quarterly Report

Short answer

ResMed (RMD) filed its Q3 2026 10-Q quarterly report on Oct 30, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.4B (up 5.9% year over year) with net income of $418M.

Q3 2026 key financials · XBRL

Revenue
$1.4B
+5.9% YoY
Net income
$418M
+20.0% YoY
Operating margin
32.0%
Gross margin
61.5%
EPS (diluted)
$2.92
+23.2% YoY

Source: XBRL data from the ResMed (RMD) Q3 2026 10-Q on SEC EDGAR. USD.

ResMed Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $1,415M, up $79M or 6% YoY
  • Gross margin 61.5% vs 61.2% YoY; net income $418M vs $349M
  • Best segment: Sleep and Breathing Health $1,260M, up 8%; worst: Residential Care Software $155M, down 7%
  • Cash $1.0B vs $1.5B at June 30; operating cash flow $422M vs $457M
  • $936M share repurchases and $250M debt repayment; inflationary component costs expected through fiscal 2027

Risk Factors

  • No material changes to the fiscal 2026 Form 10-K risk factors as of September 30, 2026
  • Carried-forward risks include regulatory compliance, product quality, cybersecurity, competition, and market demand
  • Financial exposures remain those identified in the fiscal 2026 Form 10-K, including liquidity, debt, currency, and customer concentration risks

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other ResMed quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.